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Abstract
Background: In vitro modelling of cancer cells is becoming more complex due to prevailing evidence of intimate
interactions between cancer cells and their surrounding stroma. A co-culture system which consists of more than
one cell type is physiologically more relevant and thus, could serve as a useful model for various biological studies.
An assay that specifically detects the phenotypic changes of cancer cells in a multi-cellular system is lacking for
nasopharyngeal carcinoma (NPC).
Results: Here, we describe a luciferase/luciferin (XenoLuc) assay that could specifically measure changes in the
proliferation of cancer cells in the co-culture system using two modified NPC patient-derived tumour xenograft
(PDTXs) cells: Xeno284-gfp-luc2 and XenoB110-gfp-luc2. Through this assay, we are able to show that the growth of
NPC xenograft cells in both two-dimensional (2D) and three-dimensional (3D) models was enhanced when co-
cultured with normal human dermal fibroblasts (NHDFs). In addition, potential applications of this assay in in vitro
drug or inhibitor screening experiments are also illustrated.
Conclusions: XenoLuc assay is specific, sensitive, rapid and cost-effective for measuring the growth of luciferase-
expressing cells in a co- or multiple-culture system. This assay may also be adapted for tumour microenvironment
studies as well as drug screening experiments in more complex 3D co-culture systems.
Keywords: Luciferase assay, Luminescence, Nasopharyngeal carcinoma, Nasopharyngeal neoplasms, Patient-derived
xenograft, Fibroblasts, Tumour microenvironment, Stromal interaction, Proliferation, Co-culture, Spheroids, Drug
screening, Cancer immunology
Background
Cell-based assays remain the leading platform for cancer
research in preclinical settings. Majority of high-
throughput compound screening programmes carried
out by major pharmaceutical companies utilise cell-
based assays to identify high-quality leads [1]. Such as-
says have the advantage over biochemical-based assays
since these assays provide information on the cellular
responses of a particular drug candidate. Moreover, cell-
based assays could be reliably used to provide early indi-
cations of drug toxicity [1]. The recent advancement in
cell culture technology has paved way for the develop-
ment of in vitro cell-based assays that could be carried
out in a more biologically relevant microenvironments.
Such assays may include the incorporation of extracellu-
lar matrices (ECMs) and scaffolds as well as stromal cells
in the presence of tumour cells [2, 3]. However, chal-
lenges remain in the design of these assays, particularly
on measuring phenotypic changes of a specific cell
population in complex multi-cell type systems. Notably,
there is a scarcity of convenient cell-based assays that
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could discriminate phenotypes of different cell types in a
co-culture setting [4, 5]. With greater understanding of
the microenvironment surrounding a tumour, it is in-
creasingly important to employ appropriate in vitro as-
says that are able to address issues of tumour complexity
and heterogeneity [2].
Cancer cells are often grown as monolayers, of which
2D (monolayer) culture models are commonly employed
for in vitro drug testing. However, these 2D models are
bound by several limitations that may potentially negate
their usefulness. For example, there is a lack of 3D cell-
cell and cell-ECM interactions in 2D models that are
present in in vivo models [6]. These interactions generate
signalling cues that are pivotal for numerous important
cellular functions such as proliferation, differentiation and
survival. Most of these functions are lost or have been
compromised in 2D culture models. As a result, data gen-
erated from 2D in vitro drug testing could be misleading
and non-predictive for in vivo responses [6]. The spatial
arrangement of cancer cells within the 3D model, possibly
together with the presence of other cell types and ECM
components, mimic their natural microenvironment and
hence, may reinstate the important signalling that are lost
or compromised in 2D culture systems [7]. For these rea-
sons, 3D culture models offer greater clinical and bio-
logical relevance than in vitro models and therefore, could
bridge the gap between the monolayer culture and animal
works.
Our group had developed two PDTXs, XenoB110 and
Xeno284 from Malaysian NPC patients [8]. To facilitate
the monitoring of in vivo tumour growth, these PDTXs
were co-transduced with gfp-luc2 reporter genes
(XenoB110-gfp-luc2 and Xeno284-gfp-luc2). The Xeno-
Luc assay described in this paper is a luciferase-based
assay that uses commercial D-Luciferin as the substrate
for the luciferase in the transduced PDTXs to generate a
luminescent signal that is proportional to cell numbers.
We demonstrate that the XenoLuc assay is sensitive and
could specifically measure real-time proliferation of
PDTXs both in vitro and in vivo. As 3D models are gain-
ing prominence as in vitro cell-based assays, we also
demonstrate the robustness of XenoLuc assay in both
mono- and multi-cellular spheroid cultures in addition
to the conventional 2D monolayer model. This assay is
able to measure the PDTXs growth enhancement that
resulted from the addition of growth supplements as
well as from the effect of co-culturing with other human
cell types. In addition, the assay may also be used to
evaluate the loss of cell viability, such as that induced by
cisplatin treatment. Since the proliferation and viability
of PDTX cells could be specifically detected in the com-
plex 3D co-culture systems, XenoLuc assay may repre-
sent a cost-effective and a potentially useful cell-based
assay for studies on tumour microenvironment, high-
throughput compound screening and preclinical drug
response prediction.
Results
Specificity and sensitivity of XenoLuc assay
The specificity of XenoLuc assay was assessed by deter-
mining if it specifically detected luminescent signals
from luciferase-expressing cells compared to non-
expressing cells. All experiments were carried out using
freshly isolated xenograft cells harvested from three sep-
arate tumours from different mice and used for not
more than two passages. Non-treated/non-cultured cells
are used in assays as internal controls to avoid batch-to-
batch variation which could arise from multiple causes.
Based on Fig. 1a, luminescence was detected in luc2-
transduced xenograft cells but not in parental xenograft
cells and NHDFs, indicating the specificity of XenoLuc
assay. Additional file 1: Figure S1 shows the linear cor-
relation between luminescence signals versus various ti-
trations of XenoB110-gfp-luc2 and Xeno284-gfp-luc2
cells measured at day-0 (30 min after cell seeding when
the cells had settled at the bottom of wells, but had not
adhered). The mouse cell-depleted xenograft cells exhib-
ited higher luminescent signals compared to the non-
depleted xenograft cells (Fig. 1a and b). To examine the
assay sensitivity, two-fold serial dilutions of cells were
plated and the readings were taken after 4 days. Figure 1b
shows that cell seeding number had a positive linear cor-
relation with luminescence in both 2D and 3D culture
models, of which the lowest seeding density tested was
2500 cells/well in a 96-well plate. Overall in 2D and 3D
models, XenoB110-gfp-luc2 cells exhibited higher signals
(about 20-fold) than Xeno284-gfp-luc2 cells. This could
be due to a higher expression of luciferase in XenoB110-
gfp-luc2 cells.
We then asked whether XenoLuc assay could be used
to measure cell proliferation. Figure 1c shows that the
luminescent signals increased in a time-dependent man-
ner whereby the maximum growth of both xenograft
cells was recorded at Day 6 and Day 4 for 2D and 3D
culture models, respectively. Following that, the growth
of both xenograft cells either reached plateau phase or
declined. In another experiment, we captured the images
of XenoB110-gfp-luc2 cells (2D and 3D cultures) under
FITC channel using IN-Cell high content cellular ana-
lyser, and the GFP images were subjected to fluorescence
intensity analysis by the IN-Cell Developer software.
Additional file 2: Figure S2A and S2B show that the
fluorescence intensity of non-depleted and mouse cell-
depleted xenograft cells in 2D culture correlated posi-
tively to the number of cells seeded. The signal intensity
also increased following the increase in cell proliferation
from day 2 to 4. Similar correlations (between signal in-
tensity and cell seeding numbers) were seen when
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XenoB110-gfp-luc2 cells were grown as 3D spheroids
(Additional file 2: Figure S2C). However, in these 3D
cultures, unlike luminescence signals, no obvious differ-
ence was found in fluorescence intensity between day-2
and day-4 readings.
Characterization of XenoLuc assay
The principle of XenoLuc assay was illustrated in Fig. 2a.
Light or luminescence is generated as the result of the
enzymatic reaction between the D-Luciferin substrate
and the intracellular luciferase in the presence of oxygen
and adenosine triphosphate (ATP). In addition to the lu-
minescence, other by-products are oxyluciferin, AMP,
PPi (pyrophosphate), and carbon dioxide [9]. Figure 2b
shows that the XenoLuc luminescent assay may be used
either as endpoint (lytic) or non-destructive (non-lytic)
assays. In line with the current trend of multiplexing
cell-based assays, the non-lytic assay is preferable to the
A
B
C
Fig. 1 XenoLuc assay for in vitro cell proliferation measurement. a Measurement of luminescence in two-fold serially diluted non-depleted xenograft
cells (parental and modified) and NHDF cells. These cells were seeded onto 96-well plates as 2D monolayer culture, and the luminescence was
measured after 4 days. b Measurement of luminescence of mouse cell-depleted xenograft cells cultured in vitro in 2D and 3D models. c Proliferation
rate of depleted xenografts cells as measured by XenoLuc assay at a 2-day interval. Results are represented by average of triplicate from 3 mice ± SD.
Left panel: XenoB110-gfp-luc2; Right panel: Xeno284-gfp-luc2. R2 shows the linear correlation of luminescence and cell number
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traditional endpoint assay because no cell lysis is re-
quired, and the same well may be multiplexed for vari-
ous assays [10]. Comparatively, the luminescent signals
detected by XenoLuc assay were relatively lower than
that of commercial assays (Fig. 2b). RealTime-Glo and
CellTiter-Glo employ exogenous luciferase and possibly
more sensitive proprietary luciferin substrate along with
other signal enhancers or co-factors such as Mg2+, re-
combinant ATP and Coenzyme A (CoA) [11]. The non-
lytic version of XenoLuc assay was found to give higher
signals than the lytic version of the assay at various
tested cell numbers (Fig. 2b). We then assessed the
luminescent signal stability of the XenoLuc assay in
comparison with RealTime-Glo by recording the signals
for 60 min at a 1-min interval. Figure 2c shows that the
signals in both assays initially dropped from the first
reading, and eventually stabilized after 10 min of incuba-
tion. These signals were stable for up to 60 min. We
then selected 10 min as the incubation time for luciferin
substrate with the luc2-expressing cells for subsequent
experiments. As shown in Fig. 2d, the increase of D-
luciferin substrate concentration to 2X from 1X
increased the luminescence signal by 1.5 folds. The in-
crement in signal declined when D-luciferin substrate
A
B
C
D
Fig. 2 Characterization of XenoLuc assay. a Diagram showing the basic concept of luciferase/luciferin system. b Comparison of signal intensity
detected by XenoLuc assay and two commercial assays: CellTiter-Glo (lytic) and RealTime-Glo (non-lytic). c Comparison of signal stability of
XenoLuc and RealTime-Glo. d Cytotoxicity of D-Luciferin substrate after 24-h incubation as determined by MTS assay. Results are represented by
average of triplicate from 3 mice ± SD
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was used at higher concentrations of 4X and 8X. More
importantly, the presence of luciferin at 2X for 24 h did
not cause toxicity to XenoB110-gfp-luc2 cells (Fig. 2d).
This is consistent with Tiffen et.al [12]. However, cell
viability was reduced to 89 and 73%, respectively when
incubated with 4X and 8X luciferin substrate (Fig. 2 d).
This explains the reduction in luminescent signals at
these concentrations. Similar trends were also observed
in Xeno284-gfp-luc2 cells (data not shown).
XenoLuc assay for anti-cancer drug screening
Figure 3 shows that cisplatin exhibited dose-dependent
cytotoxicity against both xenograft cells. Of the two
xenograft cells, the decrease in cell viability of Xeno284-
gfp-luc2 cells were less possibly because the cells were
more resistant to cisplatin treatment (IC50 of 45 μM and
30 μM) as compared to XenoB110-gfp-luc2 cells (IC50 of
2.5 μM and 6.25 μM) in 2D and 3D culture models. A
parallel comparison revealed that the overall lumines-
cence of Xeno284-gfp-luc2 cells was lower than
XenoB110-gfp-luc2 cells, consistent with Fig. 1. Never-
theless, comparisons were made possible because of the
inclusion of untreated cells derived from the same cell
isolates and carried out within the same experimental
batch to avoid batch-to-batch variability.
Determination of xenograft cell growth in a co-culture
system
As demonstrated by Fig. 2, XenoLuc assay specifically
detected luc2-bearing tumour cells. Additionally, it
A
B
Fig. 3 Inhibition of NPC xenograft cell viability by cisplatin as measured by XenoLuc assay. Xenograft cells (1 × 104 cells/well) were seeded onto
96-well plates (a: 2D model; b: 3D model) and treated with various concentrations of cisplatin as described in Methods. Luciferase activities were
measured at Day 3. Results are represented by average of triplicate from 3 mice ± SD
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would be beneficial if it could be used to measure the
growth of tumour cells (either inhibition or enhance-
ment) that were co-cultured with other cell types. To
validate the use of XenoLuc assay in this application, we
co-cultured the xenograft cells with either fibroblasts
(NHDFs) (adherent cells) or PBMCs (suspension cells),
and measured the luminescence signals to examine the
growth inhibition or enhancement of xenograft cells.
Figure 4a shows that the NHDFs enhanced xenograft
cell growth in 2D culture model. However, only
XenoB110-gfp-luc2 cells displayed a significant growth
enhancement (p < 0.05). The growth enhancement in
XenoB110-gfp-luc2 cells was also dependent on the num-
ber of seeded NHDFs (Additional file 3: Figure S3A). Co-
culture of xenograft cells with PBMCs did not yield any
significant difference in the growth as compared to that of
monoculture (Fig. 4b and Additional file 3: Figure S3B).
We then investigated whether this enhancing effect was
reproducible in 3D culture model. Similarly, NHDFs
significantly promoted XenoB110-gfp-luc2 cell growth in
a seeding number-dependent manner (p < 0.05) (Fig. 4b
and Additional file 3: Figure S3B). Figure 5 shows the
microscopic analysis of GFP-labelled xenograft cells co-
cultured with NHDFs and PBMCs individually in 3D
models. Xenograft cell-NHDF co-cultures resulted in ir-
regular and multiple spheroids compared to xenograft
cell-PBMC co-cultures. Consistent with the luminescence
data, the fluorescence intensity analysis showed that
NHDFs promoted the growth of XenoB110-gfp-luc2 cells
in both 2D and 3D cultures (Additional file 4: Figure S4).
Discussion
In the present study, we developed a specific and sensi-
tive luciferase-based assay known as XenoLuc to detect
and measure real-time proliferation of luc2-transduced
cells. The assay used freshly isolated xenograft cells
which were passaged for not more than two times. This
approach was established to circumvent the difficulty of
A
B
Fig. 4 Measurement of luc2-modified xenograft cell growth in a co-culture system. Xenograft cells (1 × 104 cells/well) were co-cultured with two
different cell types as described in Methods in (a) 2D culture model; and (b) 3D culture model. Luminescence was measured at Day 4. Left panel:
XenoB110-gfp-luc2; Right panel: Xeno284-gfp-luc2. Results are represented by average of triplicate from 3 mice ± SD. * p < 0.05
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establishing stable cell lines of NPC and allowed the use
of xenografts which could not be propagated indefinitely
as cell lines to be used for in vitro assays. This assay
could be performed without lysing the cells, thereby
allowing repeated and multiparametric measurements at
multiple time-points in a single well (Fig. 1c). This assay
could also capture the different growth patterns of cul-
ture models as shown in Fig. 1c. Both B110 and 284, the
3D culture models stopped growing at day 4, possibly
due to the nutrient deprivation as basal RPMI1640
medium without any supplementation was used for cul-
turing 3D spheroids. The luminescent signal was found to
be stable up to 60min, and D-Luciferin at working con-
centration was not toxic to the cells after 24-h exposure
(Fig. 2c and d). We also showed that the assay is robust
and could be applied on different cell model systems.
Furthermore, it was reliably used for multiple applications,
including drug/ inhibitor screening and growth measure-
ment in a co-culture system (Figs. 3 and 4).
The luciferase/luciferin system has been adopted in vari-
ous cell-based assays, and is widely used in biomedical re-
search. This assay is sensitive, non-toxic, suitable for
various applications and does not interfere with down-
stream applications [10, 13]. Conventional luciferase-
based assays use exogenous or endogenous luciferase to
generate bioluminescence upon the addition of an exter-
nal substrate (luciferin). The amount of emitted light de-
pends on the concentration of ATP, a widely accepted
marker of viable cells that is also the limiting reactant in
luciferase-based assays. Non-viable cells are unable to
synthesize ATP and rapidly exhaust the existing ATPs
through their endogenous ATPases. Hence, the amount of
cellular ATP in viable cells determines the intensity of lu-
minescent signal which is proportionate to the viable cell
number [14, 15].
In addition to luminescence, GFP fluorescence of the
transduced cells could also be detected, in contrast to
the commercially available luminescence-based assays
(Fig. 5 and Additional file 2: Figure S2C). The current
assay utilizes dual gfp and luc2 reporters to provide
more cellular information. The endogenous luciferase
(encoded by luc2 reporter gene) in viable cells reacts
chemically with an addition of luciferin to generate a lu-
minescent signal, whereas the GFP signal (encoded by
gfp reporter gene) provides a fluorescent visualization of
transduced tumour cells. The 2-in-1 detection in Xeno-
Luc assay helps researchers to differentiate cell types in
a co-culture system. GFP signal intensity could also be
determined using imaging software as a second measure
of cell proliferation. It is noteworthy that traditional
metabolic-based viability assays such as MTT, MTS and
XTT do not discriminate the metabolic activity between
cancer and stromal cells when they are cultured to-
gether. This results in an inability to measure accurately
the viability of either cell population when the above
metabolic assays are used in co-culture systems [16]. As
luciferase and GFP expressions are confined within
transduced cancer cells, measurement of luminescence
Fig. 5 Microscopic examination of xenograft cells co-cultured with NHDFs and PBMCs in 3D culture model. 3D spheroids from xenograft cell-
NHDF co-culture tended to form irregular shapes unlike those of xenograft cell-PBMC co-culture which were single, smooth and uniformed
aggregates. (left panel: XenoB110-gfp-luc2; right panel: Xeno284-gfp-luc2)
Teow et al. BMC Biotechnology           (2019) 19:34 Page 7 of 11
and/or GFP fluorescence will accurately reflect cell pro-
liferation changes in co-cultures. However, it should be
noted that GFP fluorescence could not effectively meas-
ure the growth of 3D spheroid culture (Additional file 2:
Figure S2C) unlike luminescence (Fig. 1c). This suggests
that GFP fluorescence is less sensitive, possibly because
the GFP signals do not penetrate well enough through
the cells from within the 3D spheroids.
To demonstrate that XenoLuc assay is comparable, if
not better than commercially available luminescent as-
says, we performed some of the experiments using our
assay in parallel with CellTiter-Glo and RealTime-Glo
kits from Promega, USA. Of note, the rate-limiting fac-
tor of both commercial assays is cellular ATP, while the
supplied luciferin and luciferase are in excess. On the
other hand, the limiting factor in XenoLuc could be the
endogenous luciferase, cellular ATP, or both (Fig. 2a). By
using these commercial kits as a benchmark, we showed
that XenoLuc assay met several important criteria as a
cell proliferation or viability assay, mainly being highly
sensitive, rapid, non-toxic, quantitative, and yields stable
signals (Fig. 2b–d). In addition, a comparison of the fea-
tures among these assays was tabulated in Table 1. Des-
pite having lower signal intensity, XenoLuc assay has
several notable advantages over other luminescent as-
says which include having a lower cost per reaction
but with its performance and robustness comparable
to that of commercial assays. Thus, the XenoLuc
assay appears to be the more cost-effective option for
researchers. More importantly, XenoLuc assay may be
used to measure specifically the proliferation of gfp
and luc2-labeled cells of interest in multi-cellular sys-
tems such as co-cultures, unlike existing luminescent
assays.
As a proof that XenoLuc assay could be a reliable tool
for high-throughput screening for drug discovery, we
tested the effect of cisplatin on the viability of our NPC
xenograft cells. XenoLuc assay was able to show that al-
though both transduced xenograft cells were sensitive to
cisplatin, Xeno284-gfp-luc2 cells displayed some resist-
ance to it as consistently observed in both 2D and 3D
cultures. This observation could be attributed to the dif-
ference in disease type: Xeno-284 was established from
recurrent NPC while XenoB110 was from untreated
primary NPC. In the former, we speculate that the
patient might have developed cisplatin resistance as a re-
sult of repetitive chemotherapy.
In the past decades, tumour cell monoculture has been
used as a model for drug screening and the study of can-
cer biology. As increasing attention is drawn towards the
complexity of tumour microenvironment, a co-culture
model is believed to be more physiologically relevant for
cancer research [2, 3]. The growth of XenoB110-gfp-
luc2 cells was markedly enhanced when co-cultured with
NHDFs (Fig. 4). In addition to luminescence data, it was
also validated by the GFP fluorescence intensity analysis
that the NHDFs promoted the growth of XenoB110-gfp-
luc2 cells (Additional file 4: Figure S4). Unlike lumines-
cence measurement that is in direct proportion to ATP
levels [17], the fluorescence intensity analysis is not af-
fected by the cellular ATP levels from the co-cultures.
This growth enhancement was likely resulted from the
activation of proliferative pathways upon direct cell-cell
contact. NHDFs have been used as feeder cells to sup-
port cancer cell growth and to simulate epithelial-
stromal cell interaction and paracrine signalling in an in
vitro culture setting [18–21]. In addition, we also used
PBMCs as the co-culture partner for xenograft cells.
There were varying results in the growth of NPC xeno-
graft cells when cultured in 2D and 3D models (Fig. 4).
It could be due to the heterogeneity within PBMCs
population as well as differential cell-cell contacts due to
culture techniques.
Conclusions
In conclusion, we have developed a specific, sensitive,
real-time, non-toxic, and cost-effective luminescent
assay to measure the proliferation of luc2-transduced
cells. This robust assay known as XenoLuc assay could
be used for multiple applications ranging from a simple
experiment such as cell doubling time measurement, to
complicated studies such as cell activation and prolifera-
tion or drug sensitivity/resistance screening in a co-
culture system. This assay may serve as an important
tool to specifically examine the role of a selected cell
types in complex co-culture systems as well as for drug
screening experiments.
Table 1 Comparison of XenoLuc assay with commercial luminescent assays
Assay Lytic/ Non-lytic Price per reactiona Incubation time Signal intensity Signal stability Linearity (R2)
XenoLuc (In-house) Lytic RM 0.013 (USD 0.003) 15 min 36,133 > 1 h 0.9915
CellTiter-Glo (Promega, USA) Lytic RM 0.20 (USD 0.05) 1 h 15 min 165,000 > 1 h 0.9963
XenoLuc (In-house) Non-lytic RM 0.013 (USD 0.003) 10 min 120,960 > 1 h 0.999
RealTime-Glo (Promega, USA) Non-lytic RM 1.86 (USD 0.46) 1 h 15 min 279,400 > 1 h 0.9835
aPrice acquired from Malaysia’s distributor
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Methods
Plasmid constructs and reagents
Lentiviral constructs (pMDL, RSV-REV, and VSVg) and
gfp-luc2 DNA transfer plasmid were kindly provided by
Marco Herold (Walter and Eliza Hall Institute of Medical
Research, Melbourne, Australia). RPMI 1640 (#31800–022),
fetal bovine serum (FBS) (#10082–139), GlutaMAX supple-
ment (#35050–061), 0.05% Trypsin-EDTA (#25300–120),
Pen-Strep (#15140–122), Pen-Strep-Fungizone (#15240–
062), B-27 supplement (#17504–001), Insulin-Transferrin-
Selenium (ITS) (#41400–045), Fibroblast growth factor
(FGF)-Basic (bFGF) (#PHG0261), and Epidermal growth
factor (EGF) (#PHG0311) were obtained from Gibco, USA.
Hydrocortisone (#H0135), Collagenase Type II (#C6885),
DPBS (#D5652), HEPES (#H3375), and Sodium Bicarbon-
ate (#S5761) were purchased from Sigma-Aldrich, USA.
DNase I (#90083) and Lipofectamine 2000 (#11668–027)
were purchased from Thermo Fisher Scientific, USA. Colla-
genase/Dispase (#11097113001) was obtained from Roche,
USA. Rho kinase (ROCK) inhibitor (#SCM075) and Poly-
brene (#TR-1003-G) were obtained from Merck Millipore,
USA. XenoLight D-Luciferin substrate (#122799) was pur-
chased from PerkinElmer, USA and stored in small aliquots
at − 20 °C in the dark. CellTiter 96 AQueous One Solution
Cell Proliferation Assay (MTS) (#G3580), CellTiter-Glo Lu-
minescent Cell Viability Assay (#G7571), and RealTime-
Glo MT Cell Viability Assay (#G9711) were from Promega,
USA. Cisplatin (#15663–27-1) was purchased from Acros
Organics, USA. RBC lysis solution was purchased from
Qiagen, USA. All reagents were dissolved, stored, and used
according to the manufacturer’s instruction.
Cells and culture conditions
Primary normal human dermal fibroblasts (NHDFs)
(#C-12300) were obtained from PromoCell, Germany
and maintained using the medium and supplements sup-
plied in the fibroblast growth medium kit (#C-23110)
(PromoCell, Germany). HEK293T cells (#CRL-3216,
ATCC, USA) were maintained in high glucose DMEM
supplemented with 10% FBS (DMEM-10). Human per-
ipheral blood mononuclear cells (PBMCs) were isolated
from the blood samples collected from three donors via
Ficoll-Paque (GE Healthcare, USA) centrifugation. All
donors had agreed and signed the consent forms.
Tissue dissociation and xenograft cell culture
Human NPC xenografts (XenoB110 and Xeno284) from
NSG mice were processed as previously described by
our group [8, 22]. All experiments were performed in ac-
cordance with the protocols approved by Animal Care
and Use Committee (ACUC), Ministry of Health,
Malaysia. Briefly, mice were humanely euthanized using
carbon dioxide gas (flow rate of between 1.3 to 3.8 L/
min) or cervical dislocation by trained personnel using
protocols approved by the Animal Care and Use Com-
mittee. Harvested xenograft tumours were transferred to
cold DPBS supplemented with 1X Pen-Strep-Fungizone,
and processed immediately. Surrounding blood capillar-
ies, fat, and/or necrotic tissue were removed and washed
twice with DPBS with 1X Pen-Strep-Fungizone. The tu-
mours were minced into 2 to 4-mm fragments and incu-
bated with the appropriate dissociation solution (2 mg/
mL Collagenase Type II and 200 U/mL DNase I for
XenoB110; 1 mg/mL Collagenase/Dispase for Xeno284)
on a belly dancer shaker with a constant agitation for 1–
2 h at 37 °C, 5% CO2. This was followed with an addition
of complete growth media (RPMI-10, 1X Pen-Strep-
Fungizone, 1X B-27 Supplement, 1X ITS, 10 μM ROCK
Inhibitor, 10 ng/mL EGF, and 10 ng/mL bFGF), after
which the entire suspension was filtered through 40 μm
nylon mesh cell strainer (BD Falcon, USA). The released
cells were centrifuged at 800 rpm for 5 min. RBC lysis
solution was added onto the cells prior to centrifugation
at 800 rpm for 5 min. The cells were then processed with
the mouse cell depletion kit (MACS Miltenyi Biotec
#130–104-694) following the manufacturer’s instruction
to enrich for human NPC xenograft cells. The enriched
cells were cultured in the above mentioned complete
growth medium for 2D monolayer culture, whereas basal
RPMI-10 was used for 3D spheroid culture. The cells
were detached using 0.05% Trypsin-EDTA at 70–80%
confluence and were sub-cultured at 1:3 dilutions. To
our best experience, xenograft cells could be maintained
up to passage four (P4) in vitro in monolayer culture,
and spheroids could be formed by medium exchange
and using a commercial spheroid plate. To minimize
biological variations, we only used freshly isolated xeno-
graft cells which were passaged for up to 2 times for ex-
periments. We used the terms xenograft cells for these
cells in contrast to xenograft tumours in mice.
Lentivirus production and cell transduction
1 × 106 HEK293T cells were seeded on 10-cm culture
dishes and incubated for 24 h. The gfp-luc2 lentiviral
transfer vector with packaging and envelope plasmids
(pMDL, RSV-REV and VSVg) were combined at a ratio
of 4:2:1:1, respectively, and mixed with Lipofectamine
2000 for transfection according to the manufacturer’s
protocol. The viral supernatant was collected at 24, 48
and 72 h post-transfection. Cellular debris was pelleted
by centrifugation at 1500 rpm for 5 min at 4 °C followed
by filtration using PVDF Millex-HV filter, 0.45 μm (Milli-
pore #SLHV033RS). The filtered lentivirus supernatant
was then concentrated using Lenti-X Concentrator (Clon-
tech #PT4421–2) according to the manufacturer’s instruc-
tion. For cell transduction, the mouse cell-depleted
xenograft cells were seeded on a 10-cm culture dish and
transduced with the concentrated lentivirus at MOI 2.0 in
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the presence of 10 μg/mL Polybrene for 24 h. GFP positive
cells were selected using a FACSAria SORP (BD Biosci-
ences, USA).
XenoLuc assay
XenoLuc assay was performed as follows for both 2D and
3D culture experiments. At each time point, 2X D-
Luciferin substrate diluted in RPMI-10 was dispensed into
each cell-containing well at 1:1 ratio. The plate was gently
agitated and incubated at room temperature in the dark
for 10min to stabilize the luminescence. The luminescent
signal of each plate was then read by EnVision multi-label
plate reader (PerkinElmer) using the ultrasensitive mode.
Following the completion of a time-point reading, the D-
Luciferin containing medium was removed from the well.
The cells were washed two times gently with 200 μL
RPMI-10, and then replenished with 100 μL of fresh
complete media until the subsequent reading. Alterna-
tively, images of GFP-expressing xenograft cells from each
well were captured using IN Cell Analyzer 2000, and the
GFP fluorescence intensity was measured and compared
using the IN Cell Developer software. For the lytic-based
format of XenoLuc assay, the protocol described by Oba
and co-workers was modified and adapted [23]. Briefly,
PBS supplemented with 1% Triton X-100 and 1X protease
inhibitor cocktail (Millipore #539134) was used as cell
lysis buffer and the lysis was performed for 10min. After
lysis, the assay buffer containing 5mM MgCl2, 100mM
Tris-HCl (pH 7.8) and 2X D-Luciferin substrate was
added to the well to generate the luminescence. The plate
was immediately measured after 15-min incubation at
room temperature in the dark.
CellTiter-Glo and RealTime-Glo
CellTiter-Glo (end-point assay) and RealTime-Glo (con-
tinuous assay) were performed according to the manu-
facturer’s instructions. To examine if the XenoLight D-
Luciferin substrate reagent was toxic to the xenograft
cells, cell viability assay (CellTiter 96 Aqueous One) was
performed on xenograft cells which had been exposed to
the substrate for 24 h.
Applications of XenoLuc assay
We evaluated the suitability of the assay for inhibitor/drug
screening and co-culture studies using both 2D and 3D
culture models. For the drug screening study, cisplatin
was used as the standard drug. Xenograft cells were simi-
larly plated in 2D and 3D culture conditions as described
above. Cells were then treated with various concentrations
of cisplatin (0, 0.78, 1.56, 3.13, 6.25, 12.5, 25, and 50 μM)
for 72 h followed by the XenoLuc assay. Prior to co-
culturing, both NHDFs and PBMCs were gamma-
irradiated separately at 35Gy. For both 2D and 3D cul-
tures, 10,000 xenograft cells were seeded simultaneously
with the irradiated co-culture partner cells at 1:1 ratio into
the same well. After an incubation of 4 days, XenoLuc
assay was performed to measure the proliferation of xeno-
graft cells in the presence of either irradiated NHDFs or
PBMCs.
Statistical analysis
For each experiment using xenograft cells, three tu-
mours were harvested from three separate mice, and
each resulting xenograft cells were seeded into three
wells per isolate of xenograft cells for subsequent experi-
ments. Each data point was represented by average of
triplicate from 3 mice ± SD. GraphPad Prism 6 software
(GraphPad Software Inc.) was used to calculate the IC50
value of cisplatin against xenograft cells. R2 value was
also determined to show the linear association between
two parameters in a linear curve. SPSS version 22.0 soft-
ware (IBM SPSS, USA) was used for analysis of statis-
tical significance. One-way analysis of variance with
Bonferroni correction and Student’s t test were used to
determine if the differences between two different
groups are significant. The results presented are
mean + standard deviations. p < 0.05 was considered sta-
tistically significant.
Additional files
Additional file 1: Figure S1. Relative luminescence units (RLUs) signals
of non-adhering B110 xenografts cells. Luciferase activities were measured
30 min after cell seeding (day-0 reading). (A) XenoB110-gfp-luc2; (B)
Xeno284-gfp-luc2. (PPTX 41 kb)
Additional file 2: Figure S2. Cell proliferation analysis of XenoB110-gfp-
luc2 by GFP fluorescence intensity using IN-CELL Developer software. (A)
Non-depleted xenograft cells; (B) Mouse cell-depleted xenograft cells; (C)
3D spheroids. The images inset shows an increasing size of spheroids
captured at day 4 proportionate to cell seeding number. R2 shows the
linear correlation of luminescence and cell number. (PPTX 62 kb)
Additional file 3: Figure S3. Evaluation of xenograft cell growth by
co-culture in 2D and 3D models. Xenograft cells (1 × 104 cells/well) were
co-cultured with various cell number of NHDFs and PBMCs in both (A)
2D; and (B) 3D model. Left panel: XenoB110-gfp-luc2; Right panel:
Xeno284-gfp-luc2. (PPTX 44 kb)
Additional file 4: Figure S4. Analysis of XenoB110-gfp-luc2 cell growth
in a co-culture system by GFP fluorescence intensity using IN-CELL
Developer software. XenoB110-gfp-luc2 cells (1 × 104 cells/well) were
co-cultured with two different cell types as described in Methods in (A)
2D culture model; and (B) 3D culture model. GFP fluorescence intensity
was determined at Day 4. (PPTX 38 kb)
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